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Abstract
Background Polypharmacy is commonly applied to elderly
haemodialysis patients for treating terminal renal failure
and multiple co-morbidities. Potentially inappropriate
medications (PIMs) in multidrug regimens in geriatric
populations can be identified using specially designed
screening tools.
Objective The aims of this study were to estimate the
prevalence of PIMs by applying the Screening Tool of
Older Persons’ Prescriptions (STOPP) criteria and the
Beers criteria to elderly haemodialysis patients and to
assess the association of some risk factors with the pres-
ence of PIMs.
Methods Fifty-one elderly haemodialysis patients partici-
pated; their median age was 74 (range 65–89) years, and
77 % of them were male. Demographic data, co-morbidity
and medication lists were collected from the electronic
medical records of the patients. The STOPP criteria were
applied by two physicians independently to identify PIMs.
The association of some risk factors with PIMs were
assessed using Fisher’s exact test.
Results The patients used a median of 13 (range 7–21)
medications per day. The overall prevalence of PIMs using
the STOPP criteria was 63 %, and using the Beers criteria
was 43 %. The most prevalent PIMs were proton-pump
inhibitors. Benzodiazepines and first-generation antihis-
tamines were related to side effects such as falls in the
previous 3 months, and calcium-channel blockers were
associated with chronic constipation. The number of PIMs
was not significantly associated with number of medica-
tions, age, sex and co-morbidity.
Conclusions The STOPP criteria revealed a high preva-
lence of PIMs in a population of elderly patients receiving
haemodialysis.
Key Points
Potentially inappropriate medications according to
STOPP criteria were identified in 63 % of elderly
haemodialysis patients and in 43 % using the Beers
criteria.
Proton pump inhibitors were the most prevalent
drugs according to STOPP criteria.
The number of potentially inappropriate medications
was not significantly associated with number of
medications, age, sex and co-morbidity.
1 Background
Elderly haemodialysis patients are considered to be a vul-
nerable group due to the presence of renal failure with
underlying co-morbidities that require the use of multiple
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drugs. Drug efficacy in these patients is influenced by age-
related changes, altered nutritional state and the
haemodialysis treatment they receive. Haemodialysis alters
the pharmacokinetics and pharmacodynamics of many
drugs due to the presence of continuous changes in the fluid
balance and uraemic toxin levels, and this may increase the
risk of drug-to-drug interactions and adverse side effects in
haemodialysis patients.
International guidelines for management of patients with
renal failure point to the importance of dose reduction or
discontinuation of certain drugs and provide cautionary
notes for prescribing (Kidney Disease Improving Global
Outcome [KDIGO] 2013) [1] or recommend regular review
of medication lists (Kidney Disease Outcome Quality Ini-
tiative [KDOQI]) [2]. Several other approaches can be used
to identify potentially inappropriate medications (PIMs),
such as a targeted multidisciplinary team approach, con-
sulting with pharmacists [3–5] or using validated screening
tools [6–8]. Two recent studies used such a screening tool
called the Beers criteria [9, 10], reporting a high prevalence
of PIMs in elderly patients with chronic kidney disease and
end-stage renal disease (ESRD). The Screening Tool of
Older Persons’ Prescriptions (STOPP) was used in two
randomized trials involving geriatric populations, in which
it contributed to a significant reduction of PIMs both at the
time of discharge after acute hospitalization and up to
6 months after discharge [11], as well as reductions in the
number of falls and costs [12]. Two European studies
involving geriatric populations found that the number of
PIMs was higher when using the STOPP criteria than when
using the Beers criteria [11, 13]. However, to our knowl-
edge the STOPP criteria have not been previously applied
to elderly haemodialysis patients.
The aims of this study were to determine the prevalence
of PIMs using the STOPP criteria and the Beers criteria in
elderly haemodialysis patients and to assess the association
of age, sex, number of medications and co-morbidity as
risk factors for PIMs in this population.
2 Methods
2.1 Study Population and Data Collection
There were 102 patients treated in the dialysis centre of
Akershus University Hospital in Norway between July and
December 2012, and those aged C65 years were asked to
participate in this study. Fifty-one patients were eligible for
inclusion, and they all agreed to participate. The following
information was collected from the electronic medical
records of the patients: age, sex, number of prescribed
medications, cause of kidney disease, severity of co-mor-
bidity (classified using the Charlson Co-morbidity Index
[CCI]), time on haemodialysis and dialysis treatment quality
index (quantified as urea clearance (Kt/V)). Supplementary
information about some medication side effects was col-
lected from patient interviews, such as falls during the pre-
vious 3 months, chronic constipation (for more than
3 months before starting haemodialysis) and current dizzi-
ness when at home.
2.2 Identification of Potentially Inappropriate
Medications
PIMs were identified using the STOPP criteria and the
updated Beers Criteria [6, 14]. The STOPP criteria were
developed and validated through a Delphi consensus process
by 18 experts in geriatric pharmacotherapy and include 65
indicators to identify important drug-to-drug and drug-to-
disease interactions [6]. The STOPP criteria exhibit a high
sensitivity in detecting PIMs and good inter-rater reliability
[6, 15, 16]. Two physicians independently applied the
STOPP and Beers criteria to review the medication lists of
all of the patients included in the present study. In case of
disagreement in identified PIMs between the two raters a
consensus was achieved by open discussion.
We also collected information on the use of nephrology-
specific drugs, which are not included in STOPP criteria,
such as phosphate binders, Vitamin D analogues, active
vitamin D and erythropoietin.
2.3 Statistical Analyses
The data were analysed using SPSS statistical software
(version 20, IBM, SPSS, Chicago, IL, USA). Descriptive
statistics are presented using mean ± SD or median
(range) values. Fisher’s exact test was used to compare the
number of PIMs between groups dichotomized according
to age, sex, CCI, time in dialysis and number of medica-
tions based on those equal to or above the median versus
those below the median.
We applied a 5 % significance cut-off in two-sided tests.
Inter-rater agreement between the two raters for assess-
ments using the STOPP and Beers screening tools is pre-
sented with % agreement (proportion of cases for which the
raters agree) and kappa coefficient for 2 9 2 tables.
Strength of reliability coefficients was defined using the
following nomenclature [17]:\0.20 poor, 0.21–0.40 fair,
0.41–0.60 moderate, 0.61–0.80 good, 0.81–1.00 very good.
3 Results
The clinical and demographic characteristics of the study
population are presented in Table 1. The most common co-
morbidities were hypertension, cardiovascular disease and
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diabetes mellitus. The patients used a total of 652 medica-
tions and a median of 13 (range 7–21) different medications
each day, and of these, a median of 5.2 (range 2– 8) drugs
can be defined as nephrology-specific drugs. PIMs were
identified in 32 patients (63 %) by using STOPP criteria.
Table 2 lists the most prevalent inappropriate medications
according to the STOPP criteria. Twenty-one patients
(42 %) had one PIM and 11 patients (22 %) had two PIMs.
Nineteen patients (37 %) reported falls during the previous
3 months, nine patients (18 %) reported chronic constipa-
tion before start of dialysis and three patients (6 %) reported
dizziness. The most prevalent PIMs according to STOPP
were proton pump inhibitors at full therapeutic dosage use
(n = 11; 22 %), calcium-channel blockers (n = 7; 14 %) in
patients with chronic constipation and benzodiazepines
(n = 6; 12 %) in those prone to falls.
The number of PIMs did not differ significantly with age
(B 74 vs. [74 years, p = 0.39), sex (male vs. female,
p = 0.74), co-morbidity severity (CCI B5 vs. [5,
p = 1.00), time in haemodialysis (B8 months vs.
[8 months, p = 0.78) or number of medications (B13 vs.
[13, p = 0.56).
Beers criteria defined PIMs in 22 patients (43 %). The
most common PIM according to the Beers criteria was
proton pump inhibitors (Table 3).
The kappa coefficient between raters for the STOPP
criteria was 0.42 (0.24–0.56, 95 % CI) and for the Beers
criteria kappa was 1.0. The % agreement was 0.78 for
STOPP and 1.00 for Beers, respectively. The disagree-
ments occurred within two of the STOPP criteria on the
interpretation of adverse effects: history of falls and
chronic constipation.
4 Discussion
The prevalence of PIMs based on the STOPP criteria was
high (63 %) in this study of elderly Norwegian
haemodialysis patients. No previous studies have presented
Table 1 Characteristics of the study population (n = 51)
Sex, male 39 (77)
Age, years, median (range) 74 (65–89)
Dialysis
Time in haemodialysis, months, median (range) 8 (0–108)
Urea clearance, Kt/V, mean ± SD 1.47 ± 0.29
Arteriovenous fistula 29 (57)
Haemodialysis catheter 22 (43)
Diagnosis
Nephrosclerosis 18 (35)
Post-renal diseasea 8 (16)
Otherb 8 (16)




Charlson Co-morbidity Index, median (range) 5 (2–9)
Hypertension 47 (92)
Cardiovascular disease 28 (55)
Diabetes mellitus 21 (41)
Malignanciesc 13 (25)
Atrial fibrillation 12 (24)
COPDd 11 (22)
Number of medications, median (range) 13 (7–21)
Data are given as number (%) except where stated otherwise
a Post-renal disease = hydronephrosis, kidney-stone disease or
retroperitoneal fibrosis
b Other = kidney cancer, loss of kidney graft, amyloidosis, poison-
ing or anti-glomerular-basement-membrane nephritis
c Malignancies = prostate cancer, colorectal cancer, testicular can-
cer, lung cancer, kidney cancer, lymphoma or myelomatosis
d COPD = chronic obstructive pulmonary disease
Table 2 Potentially
inappropriate medications
identified by the Screening Tool
of Older Persons’ Prescriptions
Cardiovascular system
Calcium-channel blocker with chronic constipation 7 (14)
Aspirin ([150 mg/day) 4 (8)
Gastrointestinal system
Proton-pump inhibitor for peptic ulcer disease at full therapeutic dosage for[8 weeks 11 (22)
Loperamide 2 (4)
Central nervous system
Long-term administration of long-acting benzodiazepines 6 (12)
First-generation antihistamine (prolonged use for[1 week) 6 (12)
Tricyclic antidepressants with an opiate or calcium-channel blocker 2 (4)
Opiates 2 (4)
Endocrine system
Beta-blockers in those with diabetes mellitus and frequent hypoglycaemic episodes 1 (2)
Total number of potentially inappropriate medications 41
Data are given as number (%)
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use of the STOPP criteria in a haemodialysis population.
However, our finding are in line with two recent studies
involving patients with chronic kidney disease that applied
Beers criteria [9, 10]. In previous studies involving general
geriatric populations the prevalence of PIMs ranged widely
(21.4–79 %) when applying the STOPP criteria [18–22].
The variations between the reported prevalence of PIMs
can probably be attributed to differences in study popula-
tions [6, 11, 13, 16, 20, 23–25].
The present study chose to apply the STOPP criteria
because of their documented association with a reduction in
PIMs in randomized studies [11, 12], and because the
STOPP criteria reportedly identify more PIMs than the
Beers criteria in European elderly patients [11, 13, 23]. In
the present study, the prevalence of PIMs was higher with
the STOPP criteria than with the Beers criteria, which is in
line with previous reports [13, 26]. The inter-rater reliability
of STOPP was lower than in previous reports [6, 15, 27].
However, these differences should be interpreted with cau-
tion because of differences in study designs and populations
Previous studies involving elderly populations found
that the number of PIMs was positively associated with the
number of medications, age and number of co-morbidities
[11, 23, 25]. In contrast, the present study found no asso-
ciations between the number of PIMs and age, sex, co-
morbidity severity, time on haemodialysis and number of
medications. This difference between the studies may be
due to differences in the case mix between the populations
or the small number of participants in the present study.
This study had several limitations. The patients were
relatively old and the number of patients was small, and so
the results cannot be generalized to all patients with ESRD.
The small sample size also limited the analysis of risk
factors for PIMs, and multivariable analysis was not con-
sidered meaningful. The study did not include a compar-
ison group. Finally, the STOPP criteria were not developed
specifically for use in patients with ESRD and they do not
evaluate several drugs commonly used by patients with
renal impairment, such as phosphate binders, erythropoi-
etin, potassium binders and calcimimetics.
5 Conclusions
In conclusion, the prevalence of PIMs among elderly
haemodialysis patients was high when applying the STOPP
criteria and the Beers criteria, even though these criteria do
not evaluate nephrology-specific drugs. In contrast, the
STOPP criteria identified more PIMs compared with the
Beers criteria in our study population. This finding supports
the use of medication review to identify and avoid PIMs in
haemodialysis patients, who are typically exposed to
polypharmacy.
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Proton-pump inhibitors (over[8 weeks avoid, unless for high-risk patients, risk of Clostridium difficile infection, bone loss and
fractures)
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